137 related articles for article (PubMed ID: 30327180)
1. Itraconazole as a Noncastrating Treatment for Biochemically Recurrent Prostate Cancer: A Phase 2 Study.
Lee M; Hong H; Kim W; Zhang L; Friedlander TW; Fong L; Lin AM; Small EJ; Wei XX; Rodvelt TJ; Miralda B; Stocksdale B; Ryan CJ; Aggarwal R
Clin Genitourin Cancer; 2019 Feb; 17(1):e92-e96. PubMed ID: 30327180
[TBL] [Abstract][Full Text] [Related]
2. A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer.
Lin J; Zahurak M; Beer TM; Ryan CJ; Wilding G; Mathew P; Morris M; Callahan JA; Gordon G; Reich SD; Carducci MA; Antonarakis ES
Urol Oncol; 2013 Jul; 31(5):581-8. PubMed ID: 21816640
[TBL] [Abstract][Full Text] [Related]
3. The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen deprivation.
Keizman D; Huang P; Antonarakis ES; Sinibaldi V; Carducci MA; Denmeade S; Kim JJ; Walczak J; Eisenberger MA
Prostate; 2011 Nov; 71(15):1608-15. PubMed ID: 21432863
[TBL] [Abstract][Full Text] [Related]
4. Dutasteride monotherapy in men with serologic relapse following radical therapy for adenocarcinoma of the prostate: a pilot study.
Perrotti M; Jain R; Abriel LM; Baroni TE; Corbett AB; Tenenbaum SA
Urol Oncol; 2012; 30(2):133-8. PubMed ID: 20800512
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer.
Shulman MJ; Karam JA; Benaim EA
Urology; 2004 Apr; 63(4):732-6. PubMed ID: 15072890
[TBL] [Abstract][Full Text] [Related]
6. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.
Duchesne GM; Woo HH; Bassett JK; Bowe SJ; D'Este C; Frydenberg M; King M; Ledwich L; Loblaw A; Malone S; Millar J; Milne R; Smith RG; Spry N; Stockler M; Syme RA; Tai KH; Turner S
Lancet Oncol; 2016 Jun; 17(6):727-737. PubMed ID: 27155740
[TBL] [Abstract][Full Text] [Related]
7. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, placebo-controlled study of the effects of pomegranate extract on rising PSA levels in men following primary therapy for prostate cancer.
Pantuck AJ; Pettaway CA; Dreicer R; Corman J; Katz A; Ho A; Aronson W; Clark W; Simmons G; Heber D
Prostate Cancer Prostatic Dis; 2015 Sep; 18(3):242-8. PubMed ID: 26169045
[TBL] [Abstract][Full Text] [Related]
9. Oral fenretinide in biochemically recurrent prostate cancer: a California cancer consortium phase II trial.
Cheung E; Pinski J; Dorff T; Groshen S; Quinn DI; Reynolds CP; Maurer BJ; Lara PN; Tsao-Wei DD; Twardowski P; Chatta G; McNamara M; Gandara DR
Clin Genitourin Cancer; 2009 Jan; 7(1):43-50. PubMed ID: 19213668
[TBL] [Abstract][Full Text] [Related]
10. Association between immunosuppressive cytokines and PSA progression in biochemically recurrent prostate cancer treated with intermittent hormonal therapy.
Hawley JE; Pan S; Figg WD; Lopez-Bujanda ZA; Strope JD; Aggen DH; Dallos MC; Lim EA; Stein MN; Hu J; Drake CG
Prostate; 2020 Mar; 80(4):336-344. PubMed ID: 31899823
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer.
Martínez-Piñeiro L; Schalken JA; Cabri P; Maisonobe P; de la Taille A;
BJU Int; 2014 Oct; 114(4):608-16. PubMed ID: 24806330
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy.
Lin AM; Rini BI; Weinberg V; Fong K; Ryan CJ; Rosenberg JE; Fong L; Small EJ
BJU Int; 2006 Oct; 98(4):763-9. PubMed ID: 16796694
[TBL] [Abstract][Full Text] [Related]
13. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy.
Rini BI; Weinberg V; Fong L; Conry S; Hershberg RM; Small EJ
Cancer; 2006 Jul; 107(1):67-74. PubMed ID: 16736512
[TBL] [Abstract][Full Text] [Related]
14. Changes in PSA kinetics predict metastasis- free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents: combined analysis of 4 phase II trials.
Antonarakis ES; Zahurak ML; Lin J; Keizman D; Carducci MA; Eisenberger MA
Cancer; 2012 Mar; 118(6):1533-42. PubMed ID: 21960118
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer.
McKay RR; Gray KP; Hayes JH; Bubley GJ; Rosenberg JE; Hussain A; Kantoff PW; Taplin ME
Cancer; 2015 Aug; 121(15):2603-11. PubMed ID: 25903013
[TBL] [Abstract][Full Text] [Related]
16. Degarelix as an intermittent androgen deprivation therapy for one or more treatment cycles in patients with prostate cancer.
Boccon-Gibod L; Albers P; Morote J; van Poppel H; de la Rosette J; Villers A; Malmberg A; Neijber A; Montorsi F
Eur Urol; 2014 Oct; 66(4):655-63. PubMed ID: 24954791
[TBL] [Abstract][Full Text] [Related]
17. Testosterone Reduction of ≥ 480 ng/dL Predicts Favorable Prognosis of Japanese Men With Advanced Prostate Cancer Treated With Androgen-Deprivation Therapy.
Yamamoto S; Sakamoto S; Minhui X; Tamura T; Otsuka K; Sato K; Maimaiti M; Kamada S; Takei A; Fuse M; Kawamura K; Imamoto T; Komiya A; Akakura K; Ichikawa T
Clin Genitourin Cancer; 2017 Dec; 15(6):e1107-e1115. PubMed ID: 28882738
[TBL] [Abstract][Full Text] [Related]
18. Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer.
Liu G; Chen YH; Kolesar J; Huang W; Dipaola R; Pins M; Carducci M; Stein M; Bubley GJ; Wilding G
Urol Oncol; 2013 Feb; 31(2):211-8. PubMed ID: 21784672
[TBL] [Abstract][Full Text] [Related]
19. Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer.
Beinart G; Rini BI; Weinberg V; Small EJ
Clin Prostate Cancer; 2005 Jun; 4(1):55-60. PubMed ID: 15992463
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
Lee AK; Levy LB; Cheung R; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
